--- title: "TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS" type: "News" locale: "en" url: "https://longbridge.com/en/news/295984294.md" description: "TuHURA Biosciences (NASDAQ:HURA) reported Q3 earnings of ($0.14) per share, beating analyst estimates of ($0.15). Shares rose 7.4% to $2.47. Analyst ratings vary, with a consensus 'Moderate Buy' and a $9.00 price target. Institutional investors including Virtu Financial, JPMorgan, and Invesco recently increased their stakes in the company." datetime: "2026-08-14T23:56:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295984294.md) - [en](https://longbridge.com/en/news/295984294.md) - [zh-HK](https://longbridge.com/zh-HK/news/295984294.md) --- # TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS TuHURA Biosciences (NASDAQ:HURA - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01, FiscalAI reports. Get **TuHURA Biosciences** alerts: ## TuHURA Biosciences Trading Up 7.4% Shares of NASDAQ HURA traded up $0.17 during midday trading on Friday, reaching $2.47. The company's stock had a trading volume of 317,089 shares, compared to its average volume of 1,079,055. The company has a market cap of $157.30 million, a price-to-earnings ratio of -4.05 and a beta of -0.01. TuHURA Biosciences has a one year low of $0.41 and a one year high of $3.43. The company has a 50 day moving average price of $2.27 and a 200 day moving average price of $2.00. ## Wall Street Analyst Weigh In HURA has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of TuHURA Biosciences from a "hold" rating to a "sell" rating in a research report on Sunday, May 31st. Citigroup initiated coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set an "outperform" rating for the company. Citizens Jmp initiated coverage on TuHURA Biosciences in a report on Monday, April 27th. They set a "market outperform" rating and a $9.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of TuHURA Biosciences in a research note on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.00. **View Our Latest Report on TuHURA Biosciences** ## Institutional Inflows and Outflows Several institutional investors have recently made changes to their positions in HURA. Virtu Financial LLC acquired a new stake in shares of TuHURA Biosciences in the third quarter worth $26,000. JPMorgan Chase & Co. purchased a new position in TuHURA Biosciences in the second quarter valued at about $27,000. Invesco Ltd. acquired a new position in TuHURA Biosciences in the 2nd quarter worth about $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at about $31,000. Finally, Bank of America Corp DE bought a new stake in shares of TuHURA Biosciences in the 4th quarter valued at approximately $59,000. 0.62% of the stock is owned by hedge funds and other institutional investors. ## About TuHURA Biosciences (Get Free Report) TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company's core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies. At the heart of TuHURA's approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states. ## See Also - Five stocks we like better than TuHURA Biosciences - Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors - Quantum Leaps: Debt-Free as AI Storage Demand Accelerates - NVIDIA's $500 Billion GPU Financing Deal Fuels Path Toward $270 - Sandisk’s Margins Look Like Software. Can They Last? _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in TuHURA Biosciences Right Now? Before you consider TuHURA Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list. While TuHURA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [HURA.US](https://longbridge.com/en/quote/HURA.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [JPX.US](https://longbridge.com/en/quote/JPX.US.md) - [JPMO.US](https://longbridge.com/en/quote/JPMO.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [VIRT.US](https://longbridge.com/en/quote/VIRT.US.md) - [IVZ.US](https://longbridge.com/en/quote/IVZ.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [SONY.US](https://longbridge.com/en/quote/SONY.US.md) - [6758.JP](https://longbridge.com/en/quote/6758.JP.md) - [TSM.US](https://longbridge.com/en/quote/TSM.US.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [SNDK.US](https://longbridge.com/en/quote/SNDK.US.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) ## Related News & Research - [Analysts Offer Predictions for AURA Q1 Earnings](https://longbridge.com/en/news/295651580.md) - [TuHURA Biosciences Expands Use of Revolving Credit Facility](https://longbridge.com/en/news/295859841.md) - [TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | HURA Stock News](https://longbridge.com/en/news/295929743.md) - [Tuhura Biosciences publishes corporate deck on strategies to overcome cancer immunotherapy resistance](https://longbridge.com/en/news/295687278.md) - [Tuhura Biosciences releases corporate deck outlining strategy to tackle cancer immunotherapy resistance](https://longbridge.com/en/news/295567242.md)